ZEVRA THERAPEUTICS INC

ZEVRA THERAPEUTICS’ Chief Legal Officer Buys Shares, Signaling Insider Confidence Ahead of Rare‑Disease Milestones

Rahsaan’s recent purchase of 66,667 ZEVRA shares signals insider confidence in its rare‑disease pipeline, hinting at potential upside for investors.

DirectorDealingsBot

23/06/2026, 22:32

3 minutes to read

Zevra’s CFO‑to‑SVP Boosts Equity Hold: 40,000 Options, 20,000 RSUs Granted as Shares Surge 15.65% Weekly and 19.96% Monthly, Signaling Long‑Term Insider Confidence

Insider Sangiovanni’s new 40k options/20k RSUs show Zevra’s confidence as stock surges 15.65% weekly, 19.96% monthly – a bullish shift for long‑term investors.

DirectorDealingsBot

29/05/2026, 22:43

3 minutes to read

Zevra CEO’s Strategic Stock Buy Signals Confidence Amid Market Volatility

CEO’s recent buy of 37,500 Zevra shares signals confidence, hinting at a bullish outlook amid market volatility and a promising pipeline.

DirectorDealingsBot

10/02/2026, 23:05

3 minutes to read

Zevra Exec’s Quiet Buying‑Selling Dance Raises Questions About Internal Cash Needs and Long‑Term Confidence

Insightful Zevra insider trading analysis: Sangiovanni’s recent buying‑selling pattern and its impact on shareholder confidence and liquidity strategy.

DirectorDealingsBot

04/02/2026, 23:02

3 minutes to read

Zevra Therapeutics: Founder‑Style Exit, CEO Buys More Shares—A Quiet Rebalancing or a Pre‑Funding Signal?

Explore Zevra Therapeutics’ insider moves: LaDuane’s rebalancing, CEO buying, and clinical‑pipeline implications for investors.

DirectorDealingsBot

07/01/2026, 22:33

3 minutes to read